Kerendia, also known by its generic name finerenone, is a medication prescribed to reduce the risk of long-term kidney damage and cardiovascular events in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1][2]. It works by targeting the body's mineralocorticoid receptor (MR) and blocking its overactivation, which is a key factor in the progression of kidney disease and heart problems [3].
What does Kerendia do for the kidneys and heart?
Kerendia is indicated for patients with established CKD and type 2 diabetes who are at risk of progressive disease. Clinical trials have demonstrated that it significantly lowers the likelihood of experiencing sustained decline in kidney function, kidney failure, and cardiovascular death compared to placebo [1][2].
How does Kerendia work to protect organs?
The active ingredient in Kerendia, finerenone, acts as a non-steroidal selective mineralocorticoid receptor antagonist. By inhibiting the MR, finerenone helps to reduce inflammation and fibrosis in the kidneys and heart. These processes are implicated in the worsening of kidney disease and the development of cardiovascular complications in individuals with type 2 diabetes [3].
What are the common side effects of Kerendia?
The most frequently reported side effects of Kerendia include hyperkalemia (high potassium levels), hypotension (low blood pressure), and diarrhea [1]. Patients are advised to monitor their potassium levels as directed by their healthcare provider, as elevated potassium can be serious [4].
When does the patent for Kerendia expire?
The patent landscape for Kerendia is complex and involves multiple patents covering different aspects of the drug, including its composition of matter and methods of use. According to DrugPatentWatch.com, patent expiry dates can vary depending on the specific patent and jurisdiction, and there are often challenges and extensions to consider [5]. Information on specific patent expiry dates can be found through detailed patent databases [5].
Are there alternatives to Kerendia for managing CKD in type 2 diabetes?
Besides Kerendia, other treatment strategies for managing CKD in type 2 diabetes include optimizing blood glucose control, managing blood pressure with agents like ACE inhibitors or ARBs, and lifestyle modifications such as dietary changes and regular exercise. SGLT2 inhibitors are another class of medication that has shown significant benefits in reducing the risk of kidney and cardiovascular events in this patient population [6].
Who manufactures Kerendia?
Kerendia is developed and marketed by Bayer [1].
What are the clinical trial results for Kerendia?
Key clinical trials, such as the FIDELITY program which included the FIDELIO-DKD and FIGARO-DKD studies, evaluated the efficacy and safety of finerenone. These trials showed a statistically significant reduction in the primary composite endpoint of kidney disease progression and cardiovascular events in patients treated with Kerendia compared to placebo [2].
What are the risks of taking Kerendia?
The primary risks associated with Kerendia are related to hyperkalemia and hypotension. Patients with certain pre-existing conditions or those taking other medications that can increase potassium levels may be at higher risk. Regular monitoring of serum potassium and blood pressure is crucial during treatment [4].
Sources:
[1] https://www.kerendia.com/
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa2106033
[3] https://www.bayer.com/en/news-releases/bayer-announces-us-fda-approval-of-kerendia-finerenone-for-adult-patients-with-chronic-kidney-disease-associated-with-type-2-diabetes
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-kerendia-finerenone-reduce-risk-kidney-and-heart-complications-adults-chronic-kidney-disease
[5] https://drugpatentwatch.com/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036974/